Advertisement

Topics

Novo's semaglutide outperforms Lilly GLP-1 rival

06:07 EDT 17 Aug 2017 | pharmaphorum

Novo Nordisk's late stage diabetes candidate semaglutide has scored another victory, outperforming Eli Lilly’s Trulicity in controlling glucose levels and body weight. The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-...

Original Article: Novo's semaglutide outperforms Lilly GLP-1 rival

NEXT ARTICLE

More From BioPortfolio on "Novo's semaglutide outperforms Lilly GLP-1 rival"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Lilly
Eli Lilly and Company was founded in 1876, and is now the 9th largest pharmaceutical company based an annual sales which were just under $20bn in 2009. Orginally from the USA, Lilly now operates in over 50 countries with just under 40,000 employees. Appr...